Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Avelumab in MTAP-Deficient Advanced Urothelial Cancer
NCT03744793Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2019
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and pemetrexed in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 2 years. Started Apr 2019; status: active, not recruiting.
02
Drugs
avelumabpemetrexed
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03744793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744793.